RT Journal Article
SR Electronic
T1 Comparative Genomic Hybridization in Cartilaginous Tumors
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1721
OP 1726
VO 24
IS 3A
A1 TOSHIFUMI OZAKI
A1 DANIEL WAI
A1 KARL-LUDWIG SCHÄFER
A1 NORBERT LINDNER
A1 WERNER BÖCKER
A1 WINFRIED WINKELMANN
A1 BARBARA DOCKHORN-DWORNICZAK
A1 CHRISTOPHER POREMBA
YR 2004
UL http://ar.iiarjournals.org/content/24/3A/1721.abstract
AB Genetic aberrations in cartilaginous tumors have not yet been well characterized. We analyzed the molecular-chromosomal aberrations in 10 chondrosarcomas (four Grade-3 tumors, four Grade-2 tumors and two Grade-1 tumors) and in three benign cartilaginous tumors (two enchondromas and one chondromyxoid fibroma). Genomic imbalances were detected in 9 out of 10 cases of chondrosarcomas. The median number of changes was 7.0 per tumor (range 0-23) and the gain-to-loss ratio was 1:1.4. The most frequent gains involved 7q, 5p, or 21q and the most frequent losses were 17p, 13q, 16p, or 22q. The three benign cartilaginous tumors each had two (0 gains and two losses), six (one gain and five losses) and eight (one gain and seven losses) chromosomal aberrations. Both of the gains occurred on 13q21 and losses were frequently observed on chromosomes 19 and 22q in all three cases. Loss of chromosomes 16p, 17p, 22q, or 19 loss were common in both chondrosarcomas and benign cartilaginous tumors. However, aberrations from chromosomes 2 to 11, 14, 15, 18, or 21 were detected only in chondrosarcomas. Therefore, although the number of aberrations between benign and malignant cartilaginous tumors appears to be similar, these two entities may be differentiated by determining which chromosomes are affected. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved